Table 2. Average PK parameters of C16 in the mouse and the rat.

	Plasma, male Sprague-Dawley rat		Whole blood, male CD-1 mouse
	IV	PO	IV	IP	PO
Dose (mg/kg)	1 a	10 a	1 b	10 b	10 b
c0 (ng/mL) c	1257		76.0
cmax (ng/mL) c		32.2		107	12.5
tmax (h) c	0	2.83	0	0.25	0.25
t1/2 (h)	1.93	3.67 f	0.746	0.800	ND
MRTlast (h)	0.76	3.67	0.433	0.800	1.38
CL (L/h/kg)	4.95		45.0	0.952
Vss (L/kg)	4.77		32.6
AUClast (h∙ng/mL)	211	146	20.0	109	20.9
AUC∞ (h∙ng/mL)	215	161 f	22.4	114	ND
Dose-normalized values d
AUClast (h∙kg ng/mL/mg)	211	14.6		10.9	2.09
AUC∞ (h∙kg ng/mL/mg)	215	16.1 f		11.4	ND
Bioavailability (%) e		6.91		54.7	10.5

c₀: Maximum plasma concentration extrapolated to t = 0; c_max: Maximum plasma concentration; t_max: Time of maximum plasma concentration; t_1/2: half-life; MRT_last: Mean Residence Time, calculated to the last observable time point; CL: Clearance; V_ss: Steady state volume of distribution; AUC_last: Area under the curve, calculated to the last observable time point; AUC_∞: Area under the curve, extrapolated to infinity; ND: not determined.

^a Vehicle: DMSO.

^b Vehicle: 20% DMSO/10% (DMSO/Cremophor EL 1:1)/70% H₂O.

^c Extrapolated to t = 0.

^d Dose normalized by dividing the parameter by the nominal dose in mg/kg.

^e Bioavailability determined by dividing the individual dose normalized oral AUC by the individual dose normalized intravenous AUC value;

^f Calculated for two out of three animals.